Valuation: Genelux Corporation

Market Cap 9.41Cr 8.43Cr 7.75Cr 7.02Cr 13Cr 893.54Cr 13Cr 92Cr 37Cr 470.03Cr 35Cr 35Cr 1.48TCr P/E 2026 *
-2.57x
P/E 2027 * -2.68x
Enterprise Value 9.41Cr 8.43Cr 7.75Cr 7.02Cr 13Cr 893.54Cr 13Cr 92Cr 37Cr 470.03Cr 35Cr 35Cr 1.48TCr EV / Sales 2026 *
-
EV / Sales 2027 * 12x
Free-Float
86.3%
Yield 2026 *
-
Yield 2027 * -
1 day-2.62%
1 week+2.50%
Current month-18.97%
1 month-18.97%
3 months-32.79%
6 months-23.22%
Current year-52.98%
1 week 1.86
Extreme 1.86
2.27
1 month 1.86
Extreme 1.86
2.66
Current year 1.86
Extreme 1.86
4.99
1 year 1.86
Extreme 1.86
8.54
3 years 1.6
Extreme 1.6
18.01
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Sell

Chief Technology Officer

-9,683 0.0214%
31/08/26 Sell

Chief Executive Officer

-34,463 0.0762%
31/08/26 Sell

Chief Technology Officer

-10,257 0.0227%
Change 5-day change 1-year change 3-year change Capi.($)
-2.62%+2.50%-74.25%-85.21% 9.41Cr
-0.62%+0.50%+33.92%+60.07% 6.44TCr
+0.35%+3.20%+14.92%+84.55% 5.62TCr
+0.53%+1.96%+15.37%+106.81% 5.42TCr
-3.51%-5.20%+22.34%+49.49% 4.53TCr
-0.52%-2.20%+19.82%+97.90% 4.22TCr
+0.30%+1.41%+222.11%+933.38% 4.08TCr
+3.27%+47.96%+112.67%+96.48% 3.38TCr
+1.22%-1.39%+13.92%+46.95% 3.22TCr
-1.29%-1.72%+21.00%-6.85% 2.36TCr
Average -0.30%+4.86%+40.18%+138.36% 3.93TCr
Weighted average by Cap. -0.12%+3.64%+49.67%+161.54%

Financials

2026 *2027 *
Net sales - 78.49L 70.29L 64.66L 58.59L 1.1Cr 75Cr 1.12Cr 7.71Cr 3.1Cr 39Cr 2.95Cr 2.88Cr 123.63Cr
Net income -3.7Cr -3.31Cr -3.04Cr -2.76Cr -5.16Cr -350.94Cr -5.25Cr -36Cr -15Cr -184.6Cr -14Cr -14Cr -582.17Cr -4.09Cr -3.66Cr -3.37Cr -3.05Cr -5.71Cr -388.44Cr -5.81Cr -40Cr -16Cr -204.33Cr -15Cr -15Cr -644.38Cr
Net Debt - -
Projected Income Statement - Annual - Genelux Corporation
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
31/26/31 $2.050 -2.38% 1,25,394
29/26/29 $2.100 -4.98% 1,20,302
28/26/28 $2.210 +7.80% 5,23,909
27/26/27 $2.050 +7.33% 14,52,184
26/26/26 $1.910 -4.50% 4,94,701
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Genelux Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.100USD
Average target price
18.83USD
Spread / Average Target
+796.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genelux Corporation
  1. Stock Market
  2. Stocks
  3. GNLX Stock